These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32060423)

  • 1. PLK1/NF-κB feedforward circuit antagonizes the mono-ADP-ribosyltransferase activity of PARP10 and facilitates HCC progression.
    Tian L; Yao K; Liu K; Han B; Dong H; Zhao W; Jiang W; Qiu F; Qu L; Wu Z; Zhou B; Zhong M; Zhao J; Qiu X; Zhong L; Guo X; Shi T; Hong X; Lu S
    Oncogene; 2020 Apr; 39(15):3145-3162. PubMed ID: 32060423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polo-like Kinase-1 Regulates Myc Stabilization and Activates a Feedforward Circuit Promoting Tumor Cell Survival.
    Xiao D; Yue M; Su H; Ren P; Jiang J; Li F; Hu Y; Du H; Liu H; Qing G
    Mol Cell; 2016 Nov; 64(3):493-506. PubMed ID: 27773673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels.
    Haupenthal J; Bihrer V; Korkusuz H; Kollmar O; Schmithals C; Kriener S; Engels K; Pleli T; Benz A; Canamero M; Longerich T; Kronenberger B; Richter S; Waidmann O; Vogl TJ; Zeuzem S; Piiper A
    Neoplasia; 2012 May; 14(5):410-9. PubMed ID: 22745587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.
    Zhang Y; Du XL; Wang CJ; Lin DC; Ruan X; Feng YB; Huo YQ; Peng H; Cui JL; Zhang TT; Wang YQ; Zhang H; Zhan QM; Wang MR
    Gastroenterology; 2012 Mar; 142(3):521-530.e3. PubMed ID: 22108192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of Polo-Like Kinase 1 by BI2536 Reverses the Multidrug Resistance of Human Hepatoma Cells In Vitro and In Vivo.
    Li HY; Luo F; Li XY; Fu XF; He JF; Tian YZ; Zhu JJ; Chu XY; Zhao HL
    Anticancer Agents Med Chem; 2019; 19(6):740-749. PubMed ID: 30836927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PIM2 promotes hepatocellular carcinoma tumorigenesis and progression through activating NF-κB signaling pathway.
    Tang X; Cao T; Zhu Y; Zhang L; Chen J; Liu T; Ming X; Fang S; Yuan YF; Jiang L; Huang JD; Guan XY
    Cell Death Dis; 2020 Jul; 11(7):510. PubMed ID: 32641749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
    Zhang C; Wang X; Fang D; Xu P; Mo X; Hu C; Abdelatty A; Wang M; Xu H; Sun Q; Zhou G; She J; Xia J; Hui KM; Xia H
    Theranostics; 2021; 11(5):2108-2122. PubMed ID: 33500714
    [No Abstract]   [Full Text] [Related]  

  • 8. PARP10 suppresses tumor metastasis through regulation of Aurora A activity.
    Zhao Y; Hu X; Wei L; Song D; Wang J; You L; Saiyin H; Li Z; Yu W; Yu L; Ding J; Wu J
    Oncogene; 2018 May; 37(22):2921-2935. PubMed ID: 29515234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
    Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
    Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated FBXO45 promotes liver tumorigenesis through enhancing IGF2BP1 ubiquitination and subsequent PLK1 upregulation.
    Lin XT; Yu HQ; Fang L; Tan Y; Liu ZY; Wu D; Zhang J; Xiong HJ; Xie CM
    Elife; 2021 Nov; 10():. PubMed ID: 34779401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.
    Diab A; Foca A; Fusil F; Lahlali T; Jalaguier P; Amirache F; N'Guyen L; Isorce N; Cosset FL; Zoulim F; Andrisani O; Durantel D
    Hepatology; 2017 Dec; 66(6):1750-1765. PubMed ID: 28445592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC.
    Wang H; Tao Z; Feng M; Li X; Deng Z; Zhao G; Yin H; Pan T; Chen G; Feng Z; Li Y; Zhou Y
    Biochem Biophys Res Commun; 2020 Dec; 533(3):368-375. PubMed ID: 32962858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
    Mok WC; Wasser S; Tan T; Lim SG
    World J Gastroenterol; 2012 Jul; 18(27):3527-36. PubMed ID: 22826617
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RB/PLK1-dependent induced pathway by SLAMF3 expression inhibits mitosis and control hepatocarcinoma cell proliferation.
    Bouhlal H; Ouled-Haddou H; Debuysscher V; Singh AR; Ossart C; Reignier A; Hocini H; Fouquet G; Al Baghami M; Eugenio MS; Nguyen-Khac E; Regimbeau JM; Marcq I
    Oncotarget; 2016 Mar; 7(9):9832-43. PubMed ID: 26799423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma.
    Deng Z; Chen G; Liu S; Li Y; Zhong J; Zhang B; Li L; Huang H; Wang Z; Xu Q; Deng X
    Eur J Med Chem; 2020 Nov; 206():112697. PubMed ID: 32814244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oncolytic adenovirus selectively targets tumor-associated polo-like kinase 1 and tumor cell viability.
    Zhou J; Gao Q; Chen G; Huang X; Lu Y; Li K; Xie D; Zhuang L; Deng J; Ma D
    Clin Cancer Res; 2005 Dec; 11(23):8431-40. PubMed ID: 16322306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TRIB3 promotes hepatocellular carcinoma growth and predicts poor prognosis.
    Wang XJ; Li FF; Zhang YJ; Jiang M; Ren WH
    Cancer Biomark; 2020; 29(3):307-315. PubMed ID: 32716348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of polo-like kinase 1 leads to the suppression of osteosarcoma cell growth in vitro and in vivo.
    Liu X; Choy E; Harmon D; Yang S; Yang C; Mankin H; Hornicek FJ; Duan Z
    Anticancer Drugs; 2011 Jun; 22(5):444-53. PubMed ID: 21399492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PLK1 Is transcriptionally activated by NF-κB during cell detachment and enhances anoikis resistance through inhibiting β-catenin degradation in esophageal squamous cell carcinoma.
    Lin DC; Zhang Y; Pan QJ; Yang H; Shi ZZ; Xie ZH; Wang BS; Hao JJ; Zhang TT; Xu X; Zhan QM; Wang MR
    Clin Cancer Res; 2011 Jul; 17(13):4285-95. PubMed ID: 21610149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
    Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.